{"id":1012217,"date":"2020-08-26T08:05:53","date_gmt":"2020-08-26T06:05:53","guid":{"rendered":"https:\/\/frezzapartners.com\/?p=1012217"},"modified":"2020-08-26T08:39:53","modified_gmt":"2020-08-26T06:39:53","slug":"1012217","status":"publish","type":"post","link":"https:\/\/frezzapartners.com\/en\/1012217\/","title":{"rendered":"Accordo Gilead-Tango Therapeutics"},"content":{"rendered":"

photo by Hannah Busing<\/p>\n

 <\/p>\n

La strategia di Gilead \u00e8 continuare a puntare sull\u2019oncologia, e lo dimostrano anche le ultime scelte di business della societ\u00e0. Tre anni fa, John Milligan, AD di Gilead, aveva gi\u00e0 firmato un accordo con Tango Therapeutics, azienda biotech di Boston proprietaria di una tecnologia innovativa per sviluppare nuovi farmaci anti cancro. Ora, con il nuovo Ceo Daniel O’Da, l\u2019accordo viene ulteriormente confermato ed ampliato.<\/p>\n

Le due societ\u00e0 hanno infatti recentemente firmato un nuovo accordo del valore massimo di 6 miliardi di dollari che coprir\u00e0 15 diversi bersagli che aiutano le cellule tumorali a eludere il sistema immunitario, come si legge in un comunicato stampa<\/a> di Gilead.<\/p>\n

“Da quando, due anni fa, abbiamo firmato l’accordo iniziale siamo stati molto soddisfatti della produttivit\u00e0 della collaborazione e della qualit\u00e0 della scoperta scientifica che \u00e8 nata da questa partnership”, ha commentato William A. Lee, Executive VP of Research di Gilead. “Non vediamo l’ora di lavorare con Tango per eseguire ulteriori screening dipendenti dal contesto del cancro al fine di identificare una serie pi\u00f9 ampia di obiettivi basati sulla nostra strategia di immuno-oncologia”.<\/p>\n

“Gilead \u00e8 stato un prezioso partner strategico e un forte collaboratore scientifico e non vediamo l’ora di far progredire i programmi oltre la validazione dei target nell’ambito di questa collaborazione allargata”, ha aggiunto Barbara Weber, MD, Presidente e AD di Tango Therapeutics. “La produttivit\u00e0 della nostra piattaforma ci permette di generare obiettivi multipli utili alla collaborazione continuando a scoprirne e svilupparne in manera indipendente, con lo scopo condiviso di portare le terapie trasformazionali ai pazienti”.<\/p>\n","protected":false},"excerpt":{"rendered":"

photo by Hannah Busing   La strategia di Gilead \u00e8 continuare a puntare sull\u2019oncologia, e lo dimostrano anche le ultime scelte di business della societ\u00e0. Tre anni fa, John Milligan, AD di Gilead, aveva gi\u00e0 firmato un accordo con Tango Therapeutics, azienda biotech di Boston proprietaria di una tecnologia innovativa per sviluppare nuovi farmaci anti cancro. Ora, con il nuovo Ceo Daniel O’Da, l\u2019accordo viene ulteriormente confermato ed ampliato. Le due societ\u00e0 hanno infatti recentemente firmato un nuovo accordo del…<\/p>\n","protected":false},"author":297440,"featured_media":1012218,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[141],"tags":[2727,2633,2859],"class_list":["post-1012217","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-accordo","tag-gilead","tag-tango-therapeutics"],"acf":[],"yoast_head":"\nAccordo Gilead-Tango Therapeutics - Frezza Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/frezzapartners.com\/1012217\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Accordo Gilead-Tango Therapeutics - Frezza Partners\" \/>\n<meta property=\"og:description\" content=\"photo by Hannah Busing   La strategia di Gilead \u00e8 continuare a puntare sull\u2019oncologia, e lo dimostrano anche le ultime scelte di business della societ\u00e0. Tre anni fa, John Milligan, AD di Gilead, aveva gi\u00e0 firmato un accordo con Tango Therapeutics, azienda biotech di Boston proprietaria di una tecnologia innovativa per sviluppare nuovi farmaci anti cancro. Ora, con il nuovo Ceo Daniel O’Da, l\u2019accordo viene ulteriormente confermato ed ampliato. Le due societ\u00e0 hanno infatti recentemente firmato un nuovo accordo del...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/frezzapartners.com\/1012217\/\" \/>\n<meta property=\"og:site_name\" content=\"Frezza Partners\" \/>\n<meta property=\"article:published_time\" content=\"2020-08-26T06:05:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-08-26T06:39:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/08\/hannah-busing-Zyx1bK9mqmA-unsplash1-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frezza Partners\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frezza Partners\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/1012217\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/1012217\\\/\"},\"author\":{\"name\":\"Frezza Partners\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"headline\":\"Accordo Gilead-Tango Therapeutics\",\"datePublished\":\"2020-08-26T06:05:53+00:00\",\"dateModified\":\"2020-08-26T06:39:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/1012217\\\/\"},\"wordCount\":263,\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/1012217\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/08\\\/hannah-busing-Zyx1bK9mqmA-unsplash1-scaled.jpg\",\"keywords\":[\"accordo\",\"gilead\",\"tango therapeutics\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/1012217\\\/\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/1012217\\\/\",\"name\":\"Accordo Gilead-Tango Therapeutics - Frezza Partners\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/1012217\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/1012217\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/08\\\/hannah-busing-Zyx1bK9mqmA-unsplash1-scaled.jpg\",\"datePublished\":\"2020-08-26T06:05:53+00:00\",\"dateModified\":\"2020-08-26T06:39:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/1012217\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/frezzapartners.com\\\/1012217\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/1012217\\\/#primaryimage\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/08\\\/hannah-busing-Zyx1bK9mqmA-unsplash1-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/08\\\/hannah-busing-Zyx1bK9mqmA-unsplash1-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/1012217\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/frezzapartners.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Accordo Gilead-Tango Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/\",\"name\":\"Frezza Partners\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/frezzapartners.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\",\"name\":\"Frezza Partners\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/en\\\/author\\\/fr3zz4partn3rs\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Accordo Gilead-Tango Therapeutics - Frezza Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/frezzapartners.com\/1012217\/","og_locale":"en_US","og_type":"article","og_title":"Accordo Gilead-Tango Therapeutics - Frezza Partners","og_description":"photo by Hannah Busing   La strategia di Gilead \u00e8 continuare a puntare sull\u2019oncologia, e lo dimostrano anche le ultime scelte di business della societ\u00e0. Tre anni fa, John Milligan, AD di Gilead, aveva gi\u00e0 firmato un accordo con Tango Therapeutics, azienda biotech di Boston proprietaria di una tecnologia innovativa per sviluppare nuovi farmaci anti cancro. Ora, con il nuovo Ceo Daniel O’Da, l\u2019accordo viene ulteriormente confermato ed ampliato. Le due societ\u00e0 hanno infatti recentemente firmato un nuovo accordo del...","og_url":"https:\/\/frezzapartners.com\/1012217\/","og_site_name":"Frezza Partners","article_published_time":"2020-08-26T06:05:53+00:00","article_modified_time":"2020-08-26T06:39:53+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/08\/hannah-busing-Zyx1bK9mqmA-unsplash1-scaled.jpg","type":"image\/jpeg"}],"author":"Frezza Partners","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Frezza Partners","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/frezzapartners.com\/1012217\/#article","isPartOf":{"@id":"https:\/\/frezzapartners.com\/1012217\/"},"author":{"name":"Frezza Partners","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"headline":"Accordo Gilead-Tango Therapeutics","datePublished":"2020-08-26T06:05:53+00:00","dateModified":"2020-08-26T06:39:53+00:00","mainEntityOfPage":{"@id":"https:\/\/frezzapartners.com\/1012217\/"},"wordCount":263,"image":{"@id":"https:\/\/frezzapartners.com\/1012217\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/08\/hannah-busing-Zyx1bK9mqmA-unsplash1-scaled.jpg","keywords":["accordo","gilead","tango therapeutics"],"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/frezzapartners.com\/1012217\/","url":"https:\/\/frezzapartners.com\/1012217\/","name":"Accordo Gilead-Tango Therapeutics - Frezza Partners","isPartOf":{"@id":"https:\/\/frezzapartners.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/frezzapartners.com\/1012217\/#primaryimage"},"image":{"@id":"https:\/\/frezzapartners.com\/1012217\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/08\/hannah-busing-Zyx1bK9mqmA-unsplash1-scaled.jpg","datePublished":"2020-08-26T06:05:53+00:00","dateModified":"2020-08-26T06:39:53+00:00","author":{"@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"breadcrumb":{"@id":"https:\/\/frezzapartners.com\/1012217\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/frezzapartners.com\/1012217\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/frezzapartners.com\/1012217\/#primaryimage","url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/08\/hannah-busing-Zyx1bK9mqmA-unsplash1-scaled.jpg","contentUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/08\/hannah-busing-Zyx1bK9mqmA-unsplash1-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/frezzapartners.com\/1012217\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/frezzapartners.com\/"},{"@type":"ListItem","position":2,"name":"Accordo Gilead-Tango Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/frezzapartners.com\/#website","url":"https:\/\/frezzapartners.com\/","name":"Frezza Partners","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/frezzapartners.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0","name":"Frezza Partners","url":"https:\/\/frezzapartners.com\/en\/author\/fr3zz4partn3rs\/"}]}},"_links":{"self":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/1012217","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/users\/297440"}],"replies":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/comments?post=1012217"}],"version-history":[{"count":0,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/1012217\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media\/1012218"}],"wp:attachment":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media?parent=1012217"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/categories?post=1012217"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/tags?post=1012217"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}